Patent ID: 8865870

Claim:
An antibody or antigen binding fragment capable of binding to Chemokine (C-X-C motif) receptor 3 (CXCR3), the antibody or antigen binding fragment comprising six complementarity determining regions (CDRs): heavy chain variable domain (VH) CDR1, VH CDR2, VH CDR3, light chain variable domain (VL) CDR1, VL CDR2, and VL CDR3, wherein: VH CDR1 is selected from the group consisting of: GISFNDAA (SEQ ID NO: 116), GFTFTSYA (SEQ ID NO: 172), GFTFSNYA (SEQ ID NO: 228), GFTFTSYA (SEQ ID NO: 368), and GYTFTDYA (SEQ ID NO: 543); VH CDR2 is selected from the group consisting of: IRSKINDYGT (SEQ ID NO: 118), ISHGGSYT (SEQ ID NO: 174), ISNGGSYT (SEQ ID NO: 230), ISHGGTYT (SEQ ID NO: 370), and ISTYNGNT (SEQ ID NO: 545), VH CDR3 is selected from the group consisting of: VIDGYGSLAY (SEQ ID NO: 120), ARHPFYSGNYQGYFDY (SEQ ID NO: 176), SRPSERSHYYATSQFAY (SEQ ID NO: 232), ARHPIYSGNYQGYFDY (SEQ ID NO: 372), and ARFLSLRYFDV (SEQ ID NO: 547), VL CDR1 is selected from the group consisting of: SSVISSY (SEQ ID NO: 123), SGVNY (SEQ ID NO: 179), SSVSY (SEQ ID NO: 235), SGVNY (SEQ ID NO: 375), and SSVIY (SEQ ID NO: 550), VL CDR2 is selected from the group consisting of: STS (SEQ ID NO: 125), FTS (SEQ ID NO: 181), DTS (SEQ ID NO: 237), FTS (SEQ ID NO: 377), and ATS (SEQ ID NO: 552), and VL CDR3 is selected from the group consisting of: QQYSGYPLT (SEQ ID NO: 127), QQFTSSPYT (SEQ ID NO: 183), QQWSSSPLT (SEQ ID NO: 239), QQFTSSPYT (SEQ ID NO: 379), and QQWSSEPLT (SEQ ID NO: 554).